Becton, Dickinson and Company $BDX Stock Bought by Toth Financial Advisory Corp

Toth Financial Advisory Corp boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 65.7% during the 3rd quarter, Holdings Channel reports. The fund owned 26,897 shares of the medical instruments supplier’s stock after buying an additional 10,661 shares during the period. Toth Financial Advisory Corp’s holdings in Becton, Dickinson and Company were worth $4,815,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. SHP Wealth Management bought a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $26,000. Meeder Asset Management Inc. raised its stake in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares in the last quarter. Bayban bought a new position in Becton, Dickinson and Company in the fourth quarter worth approximately $36,000. Main Street Group LTD purchased a new stake in Becton, Dickinson and Company during the first quarter worth $29,000. Finally, Bell Investment Advisors Inc bought a new stake in Becton, Dickinson and Company during the 2nd quarter valued at $29,000. Institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,906 shares of company stock valued at $1,265,855 in the last ninety days. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.9%

Shares of BDX traded up $1.60 during mid-day trading on Thursday, hitting $181.76. 498,678 shares of the company traded hands, compared to its average volume of 2,495,309. The company has a market capitalization of $50.08 billion, a PE ratio of 54.76, a price-to-earnings-growth ratio of 12.16 and a beta of 0.21. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The business has a 50 day moving average of $181.64 and a 200 day moving average of $162.18. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the business earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company’s payout ratio is 126.51%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BDX. Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Bank of America raised their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. Royal Bank Of Canada boosted their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a report on Thursday, August 13th. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Finally, Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a report on Monday, July 6th. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and an average price target of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.